

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS

Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment¹ that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.

Leuven, BELGIUM, Boston, MA, US – May 12, 2023 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of (i) 44,669,446 new ordinary shares on May 9, 2023, for a total amount of EUR 200,000, as the result of the conversion of 8 convertible bonds, and (ii) 23,801,967 new ordinary shares on May 12, 2023, for a total amount of EUR 100,000, as the result of the conversion of 4 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 824,233,449 outstanding ordinary shares carrying voting rights (compared to 755,762,036 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

- Share capital (EUR) 79,256,161
- Total number of securities with voting rights (all ordinary shares) 824,233,449
- Total number of ordinary shares (= denominator) 824,233,449
- Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
 - 694,000 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 694,000 securities carrying voting rights (all ordinary shares);
 - 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
 - 976,874 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 976,874 securities carrying voting rights (all ordinary shares);
 - 534,688 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 534,688 securities carrying voting rights (all ordinary shares);
 - 582,248 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 582,248 securities carrying voting rights (all ordinary shares);

¹ [Press release Oxurion, 02/03/2023](#)

- 130 convertible bonds issued on March 14, 2023, and April 20, 2023, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023; and
- 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021 (as amended from time to time).

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com</p> <p>Michaël Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com</p>	<p><u>US</u> <u>Conway Communications</u> Mary T. Conway mtconway@conwaycommsir.com</p> <p><u>ICR Westwicke</u> Christopher Brinzey Tel: +1 617 835 9304 chris.brinzey@westwicke.com</p>
--	---